231 related articles for article (PubMed ID: 37061198)
1. Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia-targeting treatments.
Eriksen PL; Djernes L; Vilstrup H; Ott P
J Hepatol; 2023 Aug; 79(2):340-348. PubMed ID: 37061198
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
[TBL] [Abstract][Full Text] [Related]
3. Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy.
Hayakawa Y; Tamaki N; Nakanishi H; Kurosaki M; Tanaka Y; Inada K; Ishido S; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Kaneko S; Yasui Y; Takahashi Y; Tsuchiya K; Okamoto R; Izumi N
Intern Med; 2023 Apr; 62(7):973-978. PubMed ID: 36070941
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.
Rockey DC; Vierling JM; Mantry P; Ghabril M; Brown RS; Alexeeva O; Zupanets IA; Grinevich V; Baranovsky A; Dudar L; Fadieienko G; Kharchenko N; Klaryts'ka I; Morozov V; Grewal P; McCashland T; Reddy KG; Reddy KR; Syplyviy V; Bass NM; Dickinson K; Norris C; Coakley D; Mokhtarani M; Scharschmidt BF;
Hepatology; 2014 Mar; 59(3):1073-83. PubMed ID: 23847109
[TBL] [Abstract][Full Text] [Related]
5. Ammonia - an enduring foe - What evaluating whole body ammonia metabolism can teach us about cirrhosis and therapies treating hepatic encephalopathy.
Shawcross DL; Thabut D; Amodio P
J Hepatol; 2023 Aug; 79(2):266-268. PubMed ID: 37178732
[No Abstract] [Full Text] [Related]
6. Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis.
Haj M; Rockey DC
Am J Gastroenterol; 2020 May; 115(5):723-728. PubMed ID: 31658104
[TBL] [Abstract][Full Text] [Related]
7. Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.
Saboo K; Shamsaddini A; Iyer MV; Hu C; Fagan A; Gavis EA; White MB; Fuchs M; Heuman DM; Sikaroodi M; Iyer RK; Gillevet PM; Bajaj JS
J Hepatol; 2021 Jan; 74(1):80-88. PubMed ID: 32679299
[TBL] [Abstract][Full Text] [Related]
8. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.
Jain A; Sharma BC; Mahajan B; Srivastava S; Kumar A; Sachdeva S; Sonika U; Dalal A
Hepatology; 2022 May; 75(5):1194-1203. PubMed ID: 34822189
[TBL] [Abstract][Full Text] [Related]
9. [Prevention and treatment of hepatic encephalopathy].
Sivolap YP
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
Ahire K; Sonawale A
J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
Irimia R; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
[TBL] [Abstract][Full Text] [Related]
12. Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study.
Weiss N; Tripon S; Lodey M; Guiller E; Junot H; Monneret D; Mayaux J; Brisson H; Mallet M; Rudler M; Imbert-Bismut F; Thabut D;
Fundam Clin Pharmacol; 2018 Apr; 32(2):209-215. PubMed ID: 29239015
[TBL] [Abstract][Full Text] [Related]
13. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy for hyperammonemia.
Hadjihambi A; Khetan V; Jalan R
Expert Opin Pharmacother; 2014 Aug; 15(12):1685-95. PubMed ID: 25032885
[TBL] [Abstract][Full Text] [Related]
15. Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.
Tapper EB; Essien UR; Zhao Z; Ufere NN; Parikh ND
J Hepatol; 2022 Aug; 77(2):377-382. PubMed ID: 35367057
[TBL] [Abstract][Full Text] [Related]
16. Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy.
Alsahhar JS; Rahimi RS
Curr Opin Gastroenterol; 2019 May; 35(3):145-154. PubMed ID: 30893082
[TBL] [Abstract][Full Text] [Related]
17. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.
Bajaj JS; O'Leary JG; Tandon P; Wong F; Kamath PS; Biggins SW; Garcia-Tsao G; Lai J; Fallon MB; Thuluvath PJ; Vargas HE; Maliakkal B; Subramanian RM; Thacker LR; Reddy KR
Aliment Pharmacol Ther; 2019 Jun; 49(12):1518-1527. PubMed ID: 31032966
[TBL] [Abstract][Full Text] [Related]
18. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
Flamm SL
Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
[TBL] [Abstract][Full Text] [Related]
19. Treatment of hyperammonemia in liver failure.
Jover-Cobos M; Khetan V; Jalan R
Curr Opin Clin Nutr Metab Care; 2014 Jan; 17(1):105-10. PubMed ID: 24281376
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy.
Jesudian AB; Ahmad M; Bozkaya D; Migliaccio-Walle K
J Manag Care Spec Pharm; 2020 Jun; 26(6):750-757. PubMed ID: 32463782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
